Cynosure

Hologic Acquires 46 Percent Share of Ultrasound Medical Imaging Company

Hologic, a device manufacturer specializing in women’s health and parent company to Cynosure, has acquired approximately 46 percent of SuperSonic Imagine, a company that specializes in ultrasound medical imaging.

SuperSonic Imagine’s main shareholders, namely Bpifrance, Andera Partners, Auriga Partners, Mérieux Participations and CDC PME Croissance, holding together 10,841,409 shares, representing approximately 46 percent of the outstanding share capital of SuperSonic Imagine, sold all of their shares to Hologic at a price of €1.50 per share.

Cynosure Expands Body Contouring Technologies with TempSure Firm and SculpSure Petite Mask

Cynosure Expands Body Contouring Range

Hologic’s Cynosure division has launched two new applicators— the TempSure Firm handpiece and a petite mask for SculpSure submental treatments—to better serve the growing market for noninvasive body contouring and cellulite reduction treatments. The TempSure Firm is the latest addition to the TempSure platform, which delivers monopolar radiofrequency energy through massage heads to gently heat tissue and temporarily reduce the appearance of cellulite. The new 60mm handpiece allows practitioners to treat larger areas of the body at a faster rate, without surgery or downtime.

Aesthetic Device: Tempsure Surgical RF

Main Image: 
Cynosure Adds Surgical RF Handpiece

Cynosure TempSure Surgical radiofrequency (RF) technology—a new addition to the company’s TempSure RF platform—allows clinicians to perform both surgical and nonsurgical aesthetic procedures with a single device. With 300 watts and 4 MHz RF, the Surgical RF technology allows for precise incisions with minimal lateral thermal damage to surrounding tissues. The resulting coagulation lessens sparking and charring during procedures, which promotes quicker recovery and better healing for patients.

No, don't share this with BeautyEtc
Article free tagging: 
Articles: 

Cynosure To Distribute Nitrous Oxide and Oxygen System in Aesthetics Market

Cynosure enters into agreement with Parker Hannifin

Hologic’s Cynosure division has entered into an agreement with Porter Instrument, a business unit of Parker Hannifin Corporation, for distribution rights in the United States and Canada to Porter’s Nitronox nitrous oxide and oxygen system. Nitronox is a self-administered nitrous oxide and oxygen delivery system providing a fast-acting inhaled analgesic that helps patients manage potential discomfort and anxiety while remaining alert and conscious during their aesthetic procedures.

Hologic To Acquire Cynosure

Hologic—a developer, manufacturer and supplier of diagnostic products, medical imaging systems and surgical products—and laser manufacturer Cynosure have signed a definitive agreement for Hologic to acquire all outstanding Cynosure shares for $66.00 per share in cash, for a total cost of approximately $1.65 billion. The boards of directors of both companies have approved the transaction unanimously.

PicoSure Receives FDA Marketing Clearance for Tattoos and Pigmented Lesions

PicoSure Approved for Tattoo Removal

Laser manufacturer Cynosure has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its PicoSure picosecond laser for the removal of the full spectrum of tattoo inks as well as pigmented lesions.


The device’s new 1064nm wavelength aids in removal of black and other dark tattoo inks and complements the system’s existing 532nm and 755nm wavelengths. It will be offered as an upgrade to existing PicoSure customers, and initial shipments of the new 1064nm laser delivery system are expected to begin in the second half of 2016.


Laser Lipolysis

Main Image: 
Laser Lipolysis

The SculpSure platform from Cynosure has received 510(k) clearance for noninvasive fat reduction. SculpSure is the first hyperthermic laser treatment approved for noninvasive lipolysis of the flanks and abdomen. The hands-free device features a 1060nm laser and a flexible applicator system to disrupt subcutaneous fat cells in approximately 25 minutes with no downtime. Contact: 888.523.2233, www.cynosure.com.

No, don't share this with BeautyEtc
Articles: 

FDA Approves PicoSure 532nm Delivery System

FDA Approves PicoSure 532nm Delivery System

Cynosure has received U.S. Food and Drug Administration (FDA) clearance for its new 532nm laser delivery system for the PicoSure. The new wavelength is indicted for tattoo removal (all ink colors).

“The new 532nm Laser Delivery System further builds on the clinical and commercial success of the 755nm PicoSure for the removal of tattoos and benign pigmented lesions as well as the treatment of acne scars and wrinkles,” said Michael Davin, chairman and CEO of Cynosure. “We are pleased to offer this system as an upgrade to our current PicoSure customer base.”